Optic neuromyelitis. Update on the clinical and pathophysiological concepts of the disease
Article Sidebar
Main Article Content
Abstract
.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Wingerchuk dM, lennon va, lucchinetti cF, et al. the spectrum of neuromyelitis optica. lancet neurol. 2007;6(9):805-15.
Wingerchuk dM, Hogancamp WF, o’Brien Pc , et al. the clinical course of neuromyelitis optica (devic’s syndrome). neurology. 1999;53(5):1107-14.
Weinshenker BG. neuromyelitis optica: what it is and what it might be. lancet. 2003;361(9361):889-90. errata en: lancet. 2003;362(9383):582
albutt tc. on the ophthalmoscopic signs of spinal disease. lancet. 1870;1(2420):76-8.
devic e. Myelite subague complique de nevrite optique. Bull Med. 1894;8:1033-4.
Jacob a, Matiello M, Wingerchuk dM, et al. neuromyelitis optica: changing concepts. J neuroimmunol. 2007;187(1-2):126-38.
Polman cH, reingold sc, edan G, et al. diagnostic criteria for multiple sclerosis: 2005 revisions to the “Mcdonald criteria”. ann neurol. 2005;58(6):840-6
cabre P, Heinzlef o, Merle H, et al. Ms and neuromyelitis optica in Martinique (French West indies). neurology. 2001;56(4):507-14.
de seze J, lebrun c, stojkovic t, et al. is devic’s neuromyelitis optica a separate disease? a comparative study with multiple sclerosis. Mult scler. 2003;9(5):521-5.
Ghezzi a, Bergamaschi r, Martinelli v, et al. clinical characteristics, course and prognosis of relapsing devic’s neuromyelitis optica. J neurol. 2004;251(1):47-52
Wingerchuk dM, lennon va, Pittock sJ, et al. revised diagnostic criteria for neuromyelitis optica. neurology. 2006;66(10):1485-9.
lennon va, Wingerchuk dM, Kryzer tJ, et al. a serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. lancet. 2004;364(9451):2106-12.
lennon va, Kryzer tJ, Pittock sJ, et al. igG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J exp Med. 2005;202(4):473-7.
domingues rB, Kuster GW, lanes F, et al. recurrent neuromyelitis optica with diffuse central nervous system involvement: case report. arq neuropsiquiatr. 2004;62(2B):543-6.
Jouhadi Z, ouazzani i, abid a, et al. neuromyelite optique de devic et hepatite virale a. a propos d’une observation pediatrique. rev neurol (Paris). 2004;160(12):1198-202
Papais-alvarenga rM, Miranda-santos cM, Puccioni-sohler M, et al. optic neuromyelitis syndrome in Brazilian patients. J neurol neurosurg Psychiatry. 2002;73(4):429-35.
Fukazawa t, Yamasaki K, ito H, et al. Both the Hla-c PB1 and -drB1 alleles correlate with risk for multiple sclerosis in Japanese: clinical phenotypes and gender as important factors. tissue antigens. 2000;55(3):199-205.
Wingerchuk dM, Weinshenker BG. neuromyelitis optica: clinical predictors of a relapsing course and survival. neurology. 2003;60(5):848-53.
Pittock sJ, lennon va, Krecke K, et al. Brain abnormalities in neuromyelitis optica. arch neurol. 2006;63(3):390-6.
roemer sF, Parisi Je, lennon va, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130(Pt 5):1194-205
nakashima i, Fujihara K, Miyazawa i, et al. clinical and Mri features of Japanese patients with multiple sclerosis positive for nMo-igG. J neurol neurosurg Psychiatry. 2006;77(9):1073-5.
Pittock sJ, Weinshenker BG, lucchinetti cF, et al. neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. arch neurol. 2006;63(7):964-8.
Jarius s, Paul F, Franciotta d, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. nat clin Pract neurol. 2008;4(4):202-14.
nielsen s, nagelhus ea, amiry-Moghaddam M, et al. specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J neurosci. 1997;17(1):171-80
Manley Gt, Fujimura M, Ma t, et al. aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. nat Med. 2000;6(2):159-63.
lehmann Hc, Hartung HP, Hetzel Gr, et al. Plasma exchange in neuroimmunological disorders: Part 1: rationale and treatment of inflammatory central nervous system disorders. arch neurol. 2006;63(7):930-5
Weinshenker BG, o’Brien Pc, Petterson tM, et al. a randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. ann neurol. 1999;46(6):878-86.
Falcini F, trapani s, ricci l, et al. sustained improvement of a girl affected with devic’s disease over 2 years of mycophenolate mofetil treatment. rheumatology (oxford). 2006;45(7):913-5.
Weinstock-Guttman B, ramanathan M, lincoff n, et al. study of mitoxantrone for the treatment of recurrent neuromyelitis optica (d evic disease). arch neurol. 2006;63(7):957-63.
cree B a, lamb s, Morgan K, et al. an open label study of the effects of rituximab in neuromyelitis optica. neurology. 2005;64(7):1270-2